Stocks in play: Trillium Therapeutics Inc.
Has received Notices of Allowance from the United States Patent and Trademark Office for two patent applications covering the use of SIRPaFc for the treatment of cancer, U.S. Patent Application No. 13/320,629 (the “629 Application”, exclusively licensed to Trillium) and U.S. Patent Application No. 15/962,540. Trillium has two SIRPaFc biologics, TTI-621 and TTI-622, in clinical development. Both therapeutics target CD47, a “don’t-eat-me” signal that cancer cells use to evade immune destruction. Trillium Therapeutics Inc. shares T.TRIL are trading up $0.75 at $18.91.
Read: